Pharmacoepidemiology and Drug Safety · 2001 · 37 citations · 22 references
PharmacyPharmacologyPharmacotherapyBioavailabilityClinical PharmacologyPulmonologyBioavailability AnalysisBioavailability AssessmentBimodal DistributionMetabolic Ratio PhenotypingPhenotype InterpretationPhenotype ProfilingPhenotype-based DiscriminationPost-dose EffectTherapeutic Drug Monitoring Biomarkers
PURPOSE: To establish a useful method for acetylator phenotypification and therapeutic drug monitoring of patients receiving isoniazid. METHODS: Sixty patients with uncomplicated pulmonary tuberculosis were given a 5-mg/kg oral dose of isoniazid each. Plasma concentrations of isoniazid and its metabolite, acetyl-isoniazid, were determined by HPLC analyses at various post-dose times. From the isoniazid concentration and the concentration ratio of acetyl-isoniazid and isoniazid (metabolic ratio), phenotypification methods were assessed. RESULTS: The metabolic ratios at 3 h post-dose revealed a trimodal distribution; a fast, intermediate and slow acetylator phenotype group. The 2-h and 6-h data showed different bimodal combinations of these phenotype groups. The metabolic ratio phenotypification method could be simplified by using the HPLC data directly without converting it to absolute concentrations. CONCLUSIONS: A single-sample test based upon the plasma isoniazid concentration, combined with the metabolic ratio of acetyl-isoniazid and isoniazid, appears to be a reliable parameter for phenotype discrimination and for bioavailability testing.
22
Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
David W. Hein, Mark A. Doll, Adrian J. Fretland et al. · PubMed · 2000 · 687 citations